All reports
All KCE reports are available in Dutch, French and English under several formats. Form and language of the reports
- 2004 (2) Apply 2004 filter
- 2005 (1) Apply 2005 filter
- 2006 (4) Apply 2006 filter
- 2009 (3) Apply 2009 filter
- 2010 (4) Apply 2010 filter
- 2011 (2) Apply 2011 filter
- 2012 (2) Apply 2012 filter
- 2013 (2) Apply 2013 filter
- 2014 (2) Apply 2014 filter
- 2015 (2) Apply 2015 filter
- 2016 (3) Apply 2016 filter
- 2019 (3) Apply 2019 filter
- 2020 (1) Apply 2020 filter
- Cancer (3) Apply Cancer filter
- Cardiovascular Diseases (2) Apply Cardiovascular Diseases filter
- (-) Remove Drugs filter Drugs (31)
- Endocrine diseases, diabetes and liver diseases (3) Apply Endocrine diseases, diabetes and liver diseases filter
- Geriatrics and chronic diseases (4) Apply Geriatrics and chronic diseases filter
- Infectious diseases (5) Apply Infectious diseases filter
- Mental health and psychiatry (1) Apply Mental health and psychiatry filter
- Musculoskeletal Diseases (1) Apply Musculoskeletal Diseases filter
- Neurology and brain disease (2) Apply Neurology and brain disease filter
- Pediatrics (2) Apply Pediatrics filter
- Prevention, Screening and vaccination (4) Apply Prevention, Screening and vaccination filter
- Respiratory diseases (1) Apply Respiratory diseases filter
- Urology and kidneys (1) Apply Urology and kidneys filter
-
Guideline on the prudent prescription of antibiotics in the dental office
KCE Reports R332C
-
Proposals for a more effective antibiotic policy in Belgium
KCE Reports 311 (2019)
-
Cost-effectiveness analysis of HPV vaccination of boys in Belgium
KCE Reports 308 (2019) The vaccine for the human papilloma virus (HPV) which causes cervical cancer was introduced about ten years ago in Belgium, but only girls benefit from it. However, it is now established that this same virus is also involved in other cancers, including throat cancer. The recommendations have thus been reviewed and here, as in most western countries, it is now recommended to vaccinate boys too.
-
Statins for the primary prevention of cardiovascular events
KCE Reports 306 (2019) A healthy lifestyle remains the most effective way of avoiding cardiovascular diseases and their consequences. Yet since 2002, the annual number of people who use cholesterol-lowering drugs from the statin family increased from 400,000 to 1,500,000. Currently, 25% of the population aged 40 and above take these drugs. Despite decreases in price due to the fact that all statins now exist in generic form, their total cost still stands at 160 million euros annually.
-
Economic evaluation of novel direct acting antiviral (DAA) treatment strategies for chronic hepatitis C
KCE Reports 276 (2016)
-
Use of pneumococcal vaccines in the elderly: an economic evaluation
KCE Reports 274 (2016) Supplementary material pdf fileR274_Supplementary-file_Univariate-sensitivity-analyses (13.95 MB) pdf fileR274_Supplementary-file_Sensitivity-analyses_PPV23-price (1.1 MB) pdf fileR274_Supplementary-file_Multivariate-sensitivity-analyses_Net-benefit-Box-plots (1.16 MB) pdf fileR274_Supplementary-file_Multivariate-sensitivity-analyses_CEAFs-and-CE-planes (58.74 MB) The results are also available in a searchable spreadsheet-database format for all scenario and sensitivity analyses.
-
Future scenarios about drug development and drug pricing
KCE Reports 271 (2016)
-
Towards a better managed off-label use of drugs
KCE Reports 252 (2015)
-
Publicly funded Practice-oriented Clinical Trials
KCE Reports 246 (2015)
-
A quadrivalent vaccine against serogroup B meningococcal disease: a cost-effectiveness study
KCE Reports 231 (2014)
-
The long-term efficacy of psychotherapy, alone or in combination with antidepressants, in the treatment of adult major depression
KCE Reports 230 (2014)
-
Supportive treatment for cancer – Part 3: Treatment of pain: most common practices
KCE Reports 211 (2013)
-
Barriers and opportunities for the uptake of biosimilar medicines in Belgium
KCE Reports 199 (2013)
-
Supportive treatment for cancer - Part 2: Prevention and treatment of adverse events related to chemotherapy and radiotherapy
KCE Reports 191 (2012)
-
[Vaccine safety surveillance in Belgium : place and limits of a background rate approach]
KCE Reports 188 (2012)
-
[Economic evaluation of antiviral treatment of chronic hepatitis B in Belgium]
KCE Reports 157 (2011)
-
Pharmacological prevention of fragility fractures in Belgium
KCE Reports 159 (2011)
-
Drug reimbursement systems: international comparison and policy recommendations
KCE Reports 147 (2010)
-
[Statins in Belgium: utilization trends and impact of reimbursement policies]
KCE Reports 141 (2010)
-
Seamless care with regard to medications between hospital and home
KCE Reports 131 (2010)